Rxsight, Inc. cash flow statement
In fiscal 2025, Rxsight, Inc.'s operations generated −$15.5m of cash; it spent $3.8m on capital projects, leaving free cash flow of −$19.3m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −35 | −45 | −59 | −42 | −17 | −16 | −23 |
| Depreciation and amortisation | 4 | 4 | 4 | 4 | 4 | 3 | 4 |
| Stock-based pay | 4 | 8 | 11 | 16 | 25 | 32 | 31 |
| Capital spending | 3 | 2 | 2 | 5 | 5 | 4 | 4 |
| Free cash flow | −38 | −47 | −61 | −46 | −22 | −19 | −27 |
| Free cash flow after stock pay | −42 | −54 | −73 | −62 | −47 | −51 | −59 |
| Shares issued | — | 12 | 2 | 9 | 21 | 4 | 2 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | −4 | −9 | −4 | −1 | −1 | −11 | −10 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 7 | 7 | 7 | 9 | 8 | 8 | 8 | 7 |
| Capital spending | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 |
| Free cash flow | −0 | −5 | −9 | −6 | −2 | −2 | −12 | −11 |
| Free cash flow after stock pay | −7 | −12 | −17 | −14 | −10 | −10 | −20 | −19 |
| Shares issued | 4 | 3 | 1 | 2 | 0 | 1 | 0 | 1 |
Compare with peers
- Beta Bionics, Inc. cash flow
- Anika Therapeutics, Inc. cash flow
- Outset Medical, Inc. cash flow
- Owlet, Inc. cash flow
- Infusystem Holdings, Inc cash flow
Head to head: BBNX vs RXSTANIK vs RXSTOM vs RXSTINFU vs RXST
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies